Zusammenfassung
Von der mit fortschreitendem Lebensalter zunehmenden Prävalenz von Schilddrüsenerkrankungen sind Frauen deutlich häufiger betroffen als Männer. Symptome einer Schilddrüsenerkrankung sind oft unspezifisch und damit nicht ohne Weiteres von Symptomen des physiologischen Alterns und auch der Peri‑/Postmenopause abzugrenzen. Eine korrekte Diagnosestellung ist nicht zuletzt im Hinblick auf das in Peri‑/Postmenopause ohnehin erhöhte Osteoporose- und kardiovaskuläre Risiko relevant. Diskutiert werden (Differenzial‑)Diagnostik einschließlich zu berücksichtigender beeinflussender Faktoren sowie Therapie und Therapie-Monitoring auch in besonderen situativen Konstellationen.
Abstract
The increasing prevalence of diseases of the thyroid gland with age affects women much more than men. The symptoms of thyroid gland diseases are often unspecific and therefore cannot be differentiated from symptoms of physiological aging and also the perimenopause and postmenopause without further indications. A correct diagnosis is relevant not least with respect to the already increased osteoporotic and cardiovascular risk. This article discusses the (differential) diagnostics including influencing factors, which must be taken into account as well as treatment and treatment monitoring also in particular situative constellations.
Literatur
Bjoro T et al (2000) Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 143:639–647
Faughnan M et al (1995) Screening for thyroid disease at the menopausal clinic. Clin Invest Med 18:11–18
Bojunga J (2015) Subklinische Schilddrüsenfunktionsstörungen in der Peri- und Postmenopause. J Gynäkol Endokrinol 25:6–11
Hollowell JG et al (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499
Mishra GD, Kuh D (2012) Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. BMJ 344:e402
Stuenkel CA et al (2015) Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100:3975–4011
de los SET, Starich GH, Mazzaferri EL (1989) Sensitivity, specificity, and cost-effectiveness of the sensitive Thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med 149:526
Surks MI, Hollowell JG (2007) Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 92:4575–4582
Kratzsch J et al (2005) New reference intervals for thyrotropin and thyroid hormones based on national academy of clinical biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem 51:1480–1486
Chikunguwo S et al (2007) Influence of obesity and surgical weight loss on thyroid hormone levels. Surg Obes Relat Dis 3:631–635 (discussion 635–6)
Bremner AP et al (2012) Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab 97:1554–1562
Surks MI, Boucai L (2010) Age- and race-based serum thyrotropin reference limits. J Clin Endocrinol Metab 95:496–502
Coene KLM (2015) et al. Subclinical hypothyroidism: a ‘laboratory-induced’ condition? Eur J Endocrinol 173:499–505
Li D et al (2017) Association of biotin ingestion with performance of hormone and Nonhormone assays in healthy adults. JAMA 318:1150
Biscolla RPM, Chiamolera MI, Kanashiro I, Maciel RMB, Vieira JGH (2017) A single 10 mg oral dose of biotin interferes with thyroid function tests. Thyroid 27:1099–1100
Gold EB et al (2013) Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol 178:70–83
Avis NE et al (2015) Duration of menopausal vasomotor symptoms over the menopause transition. Jama Intern Med 175:531
Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus Progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. J Am Med Assoc 288:321–333
Gartlehner G et al (2017) Hormone therapy for the primary prevention of chronic conditions in postmenopausal women. JAMA 318:2234
Techniker Krankenkasse (2018) Gesundheitsreport 2018 Fit oder fertig? Erwerbsbiografien in Deutschland
Manson JE et al (2017) Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA 318:927
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC (2000) The colorado thyroid disease prevalence study. Arch Intern Med 160:526
Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 379:1142–1154
Gussekloo J et al (2004) Thyroid status, disability and cognitive function, and survival in old age. JAMA 292:2591
Simonsick EM et al (2009) Subclinical hypothyroidism and functional mobility in older adults. Arch Intern Med 169:2011
Oppo A, Franceschi E, Atzeni F, Taberlet A, Mariotti S (2011) Effects of hyperthyroidism, hypothyroidism, and thyroid autoimmunity on female sexual function. J Endocrinol Invest 34:449–453
Luo H et al (2018) Subclinical hypothyroidism would not lead to female sexual dysfunction in Chinese women. BMC Womens Health 18:26
Hong H et al (2015) Subclinical hypothyroidism is not a risk factor for female sexual dysfunction in Korean middle-aged women. Thyroid 25:784–788
Atis G et al (2010) Sexual dysfunction in women with clinical hypothyroidism and subclinical hypothyroidism. J Sex Med 7:2583–2590
Biondi B (2007) Cardiovascular effects of mild hypothyroidism. Thyroid 17:625–630
Hyland KA, Arnold AM, Lee JS, Cappola AR (2013) Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 98:533–540
Somwaru LL, Rariy CM, Arnold AM, Cappola AR (2012) The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 97:1962–1969
Walsh JP et al (2010) Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. J Clin Endocrinol Metab 95:1095–1104
Stott DJ et al (2017) Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 376:2534–2544
Meier C et al (2001) TSH-controlled l—Thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel thyroid study). J Clin Endocrinol Metab 86:4860–4866
Feller M et al (2018) Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism. JAMA 320:1349
Korevaar TIM (2018) Randomized, controlled trials show that treatment of subclinical hypothyroidism does not improve quality of life, cognition, blood pressure, or BMI. Clinical Thyroidology 30(11):496–499. https://doi.org/10.1089/ct.2018;30.496-499
Taylor PN et al (2014) Falling threshold for treatment of borderline elevated Thyrotropin levels—balancing benefits and risks. Jama Intern Med 174:32
Mammen JS et al (2015) Thyroid hormone therapy and risk of Thyrotoxicosis in community-resident older adults: findings from the baltimore longitudinal study of aging. Thyroid 25:979–986
Peeters RP (2017) Subclinical hypothyroidism. N Engl J Med 376:2556–2565
Carlé A, Faber J, Steffensen R, Laurberg P, Nygaard B (2017) Hypothyroid patients encoding combined MCT10 and DIO2 gene Polymorphisms May prefer L‑T3 + L‑T4 combination treatment—data using a blind, randomized, clinical study. Eur Thyroid J 6:143–151
Wiersinga WM (2017) Therapy of endocrine disease: T4 + T3 combination therapy: is there a true effect? Eur J Endocrinol 177:R287–R296
Arafah BM (2001) Increased need for Thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 344:1743–1749
Haugen BR (2009) Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 23:793–800
Mariotti S et al (1993) Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 77:1130–1134
Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B (2008) Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 159:329–341
Sawin CT et al (1994) Low serum Thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249–1252
Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA (2001) Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861–865
Abe E et al (2003) TSH is a negative regulator of skeletal remodeling. Cell 115:151–162
De Mingo Dominguez ML et al (2018) Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy. Endocrine 62:166–173
Leader A et al (2014) Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years. J Clin Endocrinol Metab 99:2665–2673
Blum MR et al (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313:2055–2065
Tan ZS et al (2008) Thyroid function and the risk of alzheimer disease<subtitle>the Framingham study</subtitle>. Arch Intern Med 168:1514
Díez JJ (2003) Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology 49:316–323
Schouten BJ, Brownlie BEW, Frampton CM, Turner JG (2011) Subclinical thyrotoxicosis in an outpatient population—predictors of outcome. Clin Endocrinol (oxf) 74:257–261
Das G et al (2012) Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol (oxf) 77:146–151
Bahn RS et al (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 17:456–520
Azizi F, Malboosbaf R (2017) Long-term Antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27:1223–1231
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Mondorf, G. Meyer und J. Bojunga geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
K. Friese, Oberaudorf
G. Gille, Lüneburg
K. Schaudig, Hamburg
A. Schwenkhagen, Hamburg
K. Vetter, Berlin
Rights and permissions
About this article
Cite this article
Mondorf, A., Meyer, G. & Bojunga, J. Schilddrüsenerkrankungen in der Peri- und Postmenopause. Gynäkologe 52, 701–712 (2019). https://doi.org/10.1007/s00129-019-4490-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00129-019-4490-y